BioMed Laboratory
 School of Life Sciences
 Nanjing University

Lab-Intro > Publications
Publications
  •   CD226 rs727088A>G polymorphism increases the susceptibility to gastric cancer in Chinese populations. Zhang, C., Z. Ding, G. Lv, J. Li, J. F. Zhang and P. Zhou. Gene. 2015;557(1):92-97.
  •   Association between the expression of T-cadherin and vascular endothelial growth factor and the prognosis of patients with gastric cancer. Wei, B., H. Shi, X. Lu, A. Shi, Y. Cheng and L. Dong. Mol Med Rep. 2015;12(2):2075-2081.
  •   The fibroblast expression of RANKL in CoCrMo-particle-induced osteolysis is mediated by ER stress and XBP1s. Wang, Z., Z. Huang, J. Gan, N. Liu, G. Zhou, T. Shi, Z. Wang, R. Wang, N. Bao, T. Guo, J. Chen, J. Zhang, L. Dong and J. Zhao. Acta Biomater. 2015;24:352-360.
  •   MicroRNA-30 Protects Against Carbon Tetrachloride-induced Liver Fibrosis by Attenuating Transforming Growth Factor Beta Signaling in Hepatic Stellate Cells. Tu, X., X. Zheng, H. Li, Z. Cao, H. Chang, S. Luan, J. Zhu, J. Chen, Y. Zang and J. Zhang. Toxicol Sci. 2015;146(1):157-169.
  •   C/EBP-beta-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer. Sun, D., C. Wang, S. Long, Y. Ma, Y. Guo, Z. Huang, X. Chen, C. Zhang, J. Chen and J. Zhang. Br J Cancer. 2015;112(9):1491-1500.
  •   Dual TNF-alpha/IL-12p40 Interference as a Strategy to Protect Against Colitis Based on miR-16 Precursors With Macrophage Targeting Vectors. Huang, Z., J. Ma, M. Chen, H. Jiang, Y. Fu, J. Gan, L. Dong, J. Zhang and J. Chen. Mol Ther. 2015;23(10):1611-1621.
  •   An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Huang, Z., J. Gan, L. Jia, G. Guo, C. Wang, Y. Zang, Z. Ding, J. Chen, J. Zhang and L. Dong. Biomaterials. 2015;48:26-36.
  •   Loss of MicroRNA-101 Promotes Epithelial to Mesenchymal Transition in Hepatocytes. Zhao, S., Y. Zhang, X. Zheng, X. Tu, H. Li, J. Chen, Y. Zang and J. Zhang. J Cell Physiol. 2015;230(11):2706-2717.
  •   Corona-directed nucleic Acid delivery into hepatic stellate cells for liver fibrosis therapy. Zhang, Z., C. Wang, Y. Zha, W. Hu, Z. Gao, Y. Zang, J. Chen, J. Zhang and L. Dong. ACS Nano. 2015;9(3):2405-2419.
  •   CD226 rs727088A>G polymorphism increases the susceptibility to gastric cancer in Chinese populations. Zhang, C., Z. Ding, G. Lv, J. Li, J. F. Zhang and P. Zhou. Gene. 2015;557(1):92-97.
  •   Association between the expression of T-cadherin and vascular endothelial growth factor and the prognosis of patients with gastric cancer. Wei, B., H. Shi, X. Lu, A. Shi, Y. Cheng and L. Dong. Mol Med Rep. 2015;12(2):2075-2081.
  •   The fibroblast expression of RANKL in CoCrMo-particle-induced osteolysis is mediated by ER stress and XBP1s. Wang, Z., Z. Huang, J. Gan, N. Liu, G. Zhou, T. Shi, Z. Wang, R. Wang, N. Bao, T. Guo, J. Chen, J. Zhang, L. Dong and J. Zhao. Acta Biomater. 2015;24:352-360.
  •   MicroRNA-30 Protects Against Carbon Tetrachloride-induced Liver Fibrosis by Attenuating Transforming Growth Factor Beta Signaling in Hepatic Stellate Cells. Tu, X., X. Zheng, H. Li, Z. Cao, H. Chang, S. Luan, J. Zhu, J. Chen, Y. Zang and J. Zhang. Toxicol Sci. 2015;146(1):157-169.
  •   C/EBP-beta-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer. Sun, D., C. Wang, S. Long, Y. Ma, Y. Guo, Z. Huang, X. Chen, C. Zhang, J. Chen and J. Zhang. Br J Cancer. 2015;112(9):1491-1500.
  •   Dual TNF-alpha/IL-12p40 Interference as a Strategy to Protect Against Colitis Based on miR-16 Precursors With Macrophage Targeting Vectors. Huang, Z., J. Ma, M. Chen, H. Jiang, Y. Fu, J. Gan, L. Dong, J. Zhang and J. Chen. Mol Ther. 2015;23(10):1611-1621.
  •   An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Huang, Z., J. Gan, L. Jia, G. Guo, C. Wang, Y. Zang, Z. Ding, J. Chen, J. Zhang and L. Dong. Biomaterials. 2015;48:26-36.
  •   Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Zhan, X., L. Jia, Y. Niu, H. Qi, X. Chen, Q. Zhang, J. Zhang, Y. Wang, L. Dong and C. Wang. Biomaterials. 2014;35(38):10046-10057.
  •   Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Zhan, X., L. Jia, Y. Niu, H. Qi, X. Chen, Q. Zhang, J. Zhang, Y. Wang, L. Dong and C. Wang. Biomaterials. 2014;35(38):10046-10057.
  •   Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Zhan, X., L. Jia, Y. Niu, H. Qi, X. Chen, Q. Zhang, J. Zhang, Y. Wang, L. Dong and C. Wang. Biomaterials. 2014;35(38):10046-10057.
  •   A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy. Zhu, Q., L. Jia, Z. Gao, C. Wang, H. Jiang, J. Zhang and L. Dong. Mol Pharm. 2014;11(10):3269-3278.